

## **Notice to Healthcare Providers and Entities** <sup>[1]</sup>

**Featured image:**



## **Notice to Healthcare Providers and Entities**



Novartis Pharmaceuticals  
Corporation  
One Health Plaza  
East Hanover, NJ 07936

July 17, 2020

**Dear Healthcare Professionals:**

As you may be aware, Novartis Pharmaceuticals Corporation recently entered into a 2019 anti-kickback agreement with the United States and the State of New York in connection with Novartis' provision of several of its ophthalmology products. We believe providing you with additional information about this global anti-kickback agreement is important, given that we will provide you with access to information about these patients.

In general terms, the government alleges that Novartis Pharmaceuticals Corporation entered the program to make and deliver and control the distribution of some drugs to certain health care providers through its global program and other programs and health care professionals, which the company provided under its distribution and other drugs. To search its safety, the government, Novartis agreed to enter a 2019 anti-kickback agreement with you. More information about this agreement can be found at the following: <https://www.novartis.com>, Novartis Press Release: <https://www.novartis.com>, Department of Health and Human Services, and Department of Justice.

As part of the settlement, Novartis also entered into a 2019 anti-kickback agreement with the Office of Inspector General of the U.S. Department of Health and Human Services. This anti-kickback agreement is available at <https://www.oig.hhs.gov>. Under this agreement, Novartis agreed to provide certain information designed to provide compliance with certain health care program anti-kickback requirements. We also agreed to notify healthcare providers about the settlement and inform them that they can report any questionable practices by Novartis representatives to Novartis Compliance Department or the OIG using the information on our Website.

Please call Novartis at 1-800-451-4511 (1-800-451-4511) or visit us at [www.novartis.com](https://www.novartis.com) for more information about the settlement referenced above. Please call Novartis at 1-800-451-4511 or visit us at [www.oig.hhs.gov](https://www.oig.hhs.gov) for more information about the settlement referenced above. Please call Novartis at 1-800-451-4511 or visit us at [www.oig.hhs.gov](https://www.oig.hhs.gov) for more information about the settlement referenced above. Please call Novartis at 1-800-451-4511 or visit us at [www.oig.hhs.gov](https://www.oig.hhs.gov) for more information about the settlement referenced above.

Sincerely,

Mark B. Smith  
President, Novartis Pharmaceuticals Corporation

## Novartis enters into Corporate Integrity Agreement with Office of Inspector General (OIG) of the US Department of Health & Human Services

[Read More \(PDF 0.1 MB\)](#) [2]

**Accordion Type:**  
Collapsible

**Source URL:** <https://www.novartis.us/news/statements/notice-healthcare-providers-and-entities>

### Links

[1] <https://www.novartis.us/news/statements/notice-healthcare-providers-and-entities>

[2] <https://www.novartis.us/sites/www.novartis.us/files/letter-to-hcps-final-2020-07-24.pdf>